Telix Clears FDA Hurdle for Expanded ProstACT Phase 3 Trial in U.S. — Telix Pharmaceuticals Limited

Event summary

Telix aligned with FDA on Part 2 of ProstACT Global Phase 3 trial for TLX591-Tx in mCRPC.
FDA approved safety data from Part 1 and agreed on clinical protocol, statistical framework.
Part 2 enrollment continues internationally; U.S. initiation pending IND amendment approval.
ProstACT Global targets ~490 patients across three standard-of-care combination cohorts.

The big picture

Telix’s alignment with the FDA marks a critical step in advancing its radiopharmaceutical pipeline, particularly for TLX591-Tx, which targets metastatic castration-resistant prostate cancer. The ProstACT Global trial’s expansion into the U.S. follows a broader industry trend toward integrating theranostics—combining diagnostics and targeted therapies—to improve cancer treatment outcomes. Telix’s ability to differentiate its product through reduced toxicity could enhance its competitive position in the growing radiopharmaceutical market.

What we're watching

Regulatory Timing: The pace at which the FDA reviews Telix’s IND amendment will determine U.S. enrollment start.
Clinical Differentiation: Whether TLX591-Tx’s liver excretion and reduced toxicity can position it as a safer alternative to existing PSMA-targeted therapies.
Global Expansion: How quickly Telix secures regulatory approvals in Europe and other regions where Part 2 is not yet approved.